TricelX

TricelX is a pre-clinical stage biotechnology company focused on developing next-generation engineered regulatory T cell (Treg) therapies. Spun out from the University of Pennsylvania, the company leverages advanced cell engineering to create targeted treatments for autoimmune diseases and organ transplant rejection. Their platform aims to restore immune balance by enhancing the suppressive function and specificity of Tregs. TricelX's approach addresses the limitations of current immunosuppressive treatments by providing a more precise and durable therapeutic effect. The company is led by experts in immunology and cell therapy and is headquartered in Philadelphia's biotech hub.